RFK Jr. casts doubts on vaccines, clashes with Democrats over Covid shot access

RFK Jr. casts doubts on vaccines, clashes with Democrats over Covid shot access


U.S. Health and Human Services Secretary Robert F. Kennedy Jr., testifies before a Senate Finance Committee hearing on President Donald Trump’s 2026 health care agenda, on Capitol Hill in Washington, D.C., U.S., September 4, 2025.

Jonathan Ernst | Reuters

Health and Human Services Secretary Robert F. Kennedy Jr. doubled down on false claims about vaccines and claimed he isn’t limiting access to Covid shots during his Senate testimony on Thursday, as senators grilled him on his sweeping changes to immunization policy and federal health agencies.

Kennedy said he supports a statement made by a newly appointed member of a key government vaccine panel that mRNA vaccines pose a dangerous risk to people. Numerous studies have demonstrated that shots using mRNA technology, including Covid vaccines from Pfizer and Moderna, are safe and effective, and serious side effects have happened in extremely rare cases.

Sen. Michael Bennet, D-Colo., noted that the committee member, Dr. Retsef Levi, has said that evidence is mounting that mRNA vaccines cause “serious harm, including death, especially among young people,” apparently referring to a post pinned on Levi’s X account. Kennedy appointed Levi to the Advisory Committee on Immunization Practices, which advises the Centers for Disease Control and Prevention on vaccine recommendations and insurance coverage.

Kennedy said he wasn’t aware of Levi’s comments, but added, “I agree with it.”

He also claimed that anyone could get a Covid booster shot, while also acknowledging that access “depends on the state” and that the government no longer recommends the vaccines for healthy people.

The Food and Drug Administration approved a fresh round of Covid shots with new limits, only clearing them for adults aged 65 and older and people with a medical condition that puts them at risk of a severe illness. The CDC and its vaccine panel will decide who to recommend the shots to later this month.

“I’m not taking them away from people,” Kennedy said, referring to the vaccines.

But Sen. Elizabeth Warren, D-Mass., argued that not everyone can walk into a pharmacy and get a Covid shot now.

The FDA’s new limits have complicated Covid shot access in the U.S., which now depends on a patient’s age and risk level, laws and policies in their state, insurance coverage, and health-care provider. Pending CDC guidance, some pharmacies have added prescription requirements for Covid vaccines in certain states.

“You clearly are taking away vaccines,” she said after a prolonged shouting match with Kennedy.

More CNBC health coverage

Kennedy’s comments before the Senate Finance Committee come after he repeatedly promised the panel in January that he would do nothing as HHS secretary that makes it more difficult or discourages people from taking vaccines. Since then, he has canceled funding for mRNA shot development and made other vaccine policy changes that could limit access to immunizations, including gutting the CDC vaccine panel and dropping Covid shot recommendations for certain groups.

His comments also follow a leadership shake-up at the Centers for Disease Control and Prevention. The White House last week fired CDC Director Susan Monarez, and four senior agency officials resigned shortly after, with some of them citing the politicization of the agency and a threat to public health. In an opinion piece on Thursday, Monarez accused Kennedy of “a deliberate effort to weaken America’s public-health system and vaccine protections.”

White House press secretary Karoline Leavitt posted on X in support of Kennedy on Thursday, writing that he “is taking flak because he’s over the target” and saying Democrats were attacking the Trump administration’s “commonsense effort.”

Kennedy touted skepticism around Covid vaccines, despite evidence of their safety and effectiveness. 

“We were told again and again the vaccines would prevent transmission, they prevent infection. It wasn’t true. They knew it from the start,” Kennedy said.  

He also said he does not know how many people died of Covid and whether the vaccines prevented deaths from the virus.

“I would like to see the data and talk about the data,” Kennedy said.

But data is readily available from dozens of studies. One paper in August estimates that Covid vaccines saved more than 2 million lives, mostly among older adults, worldwide between 2020 and October 2024. 

The CDC website also says that Covid vaccines from the 2023 to 2024 season reduced the risk of severe illness from Covid by almost 70% in the first two months after vaccination in adults ages 18 and older, with protection gradually declining over time.

Those shots also decreased the risk of hospitalization due to Covid by around 50% in the first two months of vaccination in that same population. The Covid vaccines showed similar benefits in older adults.

Kennedy also defended his decision to fire all 17 previous members of the CDC vaccine panel, saying he didn’t politicize the committee.

“What we did is we got rid of the conflicts of interest. … We depoliticized and put great scientists on it from a very diverse group,” the HHS secretary said. “They are very, very pro-vaccine.”

But a new analysis published last month from USC researchers found that conflicts of interest on that panel had been at “historic lows for years” before Kennedy restacked it with new members, some of whom are widely known vaccine critics.

Correction: Kennedy testified before the Senate Finance Committee on Thursday. An earlier version misstated the day.

Don’t miss these insights from CNBC PRO



Source

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
Health

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Wall Street is optimistic that Olema Pharmaceutical could be developing the next major breakthrough breast cancer treatment. Earlier this month, the company announced promising clinical data for its lead candidate palazestrant, an oral medication that is being evaluated in several trials for estrogen receptor-positive, or ER+, breast cancer. Shares of the clinical-stage biopharmaceutical company are up […]

Read More
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’
Health

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’

It’s been a stellar few months for shares of San Francisco-based biotech company Rigel Pharmaceuticals, which has approved treatments for rheumatology and oncology — as well as potential new drugs in the pipeline. The stock has jumped about 50% in just the last three months, earning it a spot on CNBC’s list of top performing […]

Read More
We’re raising our Eli Lilly price target — what a difference a quarter makes
Health

We’re raising our Eli Lilly price target — what a difference a quarter makes

Eli Lilly shares jumped Thursday after the drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications. The company also raised its full-year sales outlook for the second time in a row, inspiring confidence in the trajectory of the franchise. Revenue in the three months ended Sept. 30 jumped 54% year […]

Read More